Paxlovid and molnupiravir were approved in Aotearoa early in 2022 for treating COVID-19 in adults at increased risk of progressing to severe disease, hospitalisation or death. Variations in the dispensing of these medicines suggest inequitable access. Read this microlearning to find out more.

Contributor
He Ako Hiringa
2 April 2024

Chronic hepatitis C can cause cirrhosis, liver failure, cancer and early death. Raising awareness that hep C can be cured with a short course of oral antivirals is vital. Read this microlearning to find out more.

Contributor
He Ako Hiringa
1 February 2024

Metered dose inhalers such as salbutamol contain hydrofluorocarbon propellants, powerful greenhouse gases that contribute to global warming. Read this microlearning to find out more about inhaler carbon footprint and environmentally friendly alternatives. 

Contributor
He Ako Hiringa
1 December 2023

Approximately 80% of women experience perimenopause symptoms. Menopausal hormone therapy (MHT) can greatly help to improve symptom severity and frequency. Read this microlearning to find out more. 

Contributor
He Ako Hiringa
1 September 2023

Benzodiazepines and zopiclone are used frequently and for extended periods to aid sleep, despite well-recognised harms of dependency, cognitive decline and falls. Find out more about benzodiazepine and zopiclone use in Aotearoa in this piece of microlearning. 

Contributor
He Ako Hiringa
1 August 2023

With coughs and colds doing the rounds, the He Ako Hiringa Virus Action Plans can help manage patient expectations for antibiotics. Read this microlearning to learn more. 

Contributor
He Ako Hiringa
3 July 2023

Methylphenidate and dexamfetamine are now funded for up to three months’ supply when prescribed through the New Zealand ePrescription Service (NZePS). Read this microlearning to find out more. 

Contributor
He Ako Hiringa
8 June 2023